^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells

Published date:
01/30/2021
Excerpt:
Targeting MEK and ALK or MEK and PI3K/mTOR synergistically inhibits FM-MPeM-01 PDCs growth....strong synergy between ALK inhibitors (crizotinib and ceritinib) in combination with MEK (cobimetinib) and mTOR/PI3K (gedatolisib) inhibitors, respectively (Fig. 4). The synergy was more efficient for ceritinib compared to crizotinib. These results highlight the potential efficacy of these combinations in ALK-positive MPeM cancer treatment...
DOI:
https://doi.org/10.1016/j.tranon.2021.101027